• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿奇霉素对贝赫切特病细胞内细胞因子反应和黏膜皮肤表现的影响。

Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease.

机构信息

Department of Health Informatics and Technologies, Faculty of Health Sciences, Marmara University, Istanbul, Turkey.

出版信息

Int J Dermatol. 2013 Dec;52(12):1561-6. doi: 10.1111/ijd.12144. Epub 2013 Jul 24.

DOI:10.1111/ijd.12144
PMID:23879671
Abstract

OBJECTIVE

The aim of this study was to investigate the effects of azithromycin on mucocutaneous manifestations and ex vivo intracellular cytokine responses in patients with Behçet's disease (BD).

METHODS

Ten BD patients with active manifestations and nine healthy controls (HCs) were included in the study. Patients were treated with azithromycin (1500 mg/week) for four weeks. Clinical and immunological responses were evaluated in the pre- and post-azithromycin treatment periods. Peripheral blood mononuclear cells (PBMCs) of patients and controls were stimulated by Streptococcus sanguinis, lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat shock protein-60 (HSP-60) for three hours. Ex vivo intracellular interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels were measured.

RESULTS

Follicular lesions and genital ulcers completely healed, and the number of oral ulcers decreased after treatment (P = 0.000). The stimulated intracellular IFN-γ response to S. sanguinis was higher in BD patients (5.75%) than in HCs (3.9%) before treatment (P = 0.05). Likewise, the pretreatment IFN-γ response was significantly higher than the post-treatment response (1.95%). In BD patients, pretreatment stimulated intracellular IFN-γ responses to LTA (5.8%) were also higher than post-treatment responses (3.15%), but the difference did not reach statistical significance (P = 0.07).

CONCLUSIONS

Azithromycin treatment decreased the mucocutaneous manifestations in BD patients and suppressed the intracellular IFN-γ responses of PBMCs to S. sanguinis ex vivo, which suggests this treatment has an immunomodulatory effect.

摘要

目的

本研究旨在探讨阿奇霉素对 Behçet 病(BD)患者黏膜皮肤表现和细胞内细胞因子反应的影响。

方法

纳入 10 例活动性 BD 患者和 9 例健康对照(HC)。患者接受阿奇霉素(1500mg/周)治疗 4 周。在治疗前后评估临床和免疫反应。刺激患者和对照者外周血单个核细胞(PBMC) 3 小时,用链球菌、脂多糖(LPS)、脂磷壁酸(LTA)和热休克蛋白-60(HSP-60)。测量细胞内干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)水平。

结果

滤泡病变和生殖器溃疡完全愈合,口腔溃疡数量减少(P = 0.000)。治疗前 BD 患者(5.75%)对 S. sanguinis 的刺激细胞内 IFN-γ 反应高于 HC(3.9%)(P = 0.05)。同样,预处理 IFN-γ 反应明显高于治疗后反应(1.95%)。在 BD 患者中,预处理刺激的 LTA (5.8%)细胞内 IFN-γ 反应也高于治疗后反应(3.15%),但差异无统计学意义(P = 0.07)。

结论

阿奇霉素治疗可减少 BD 患者的黏膜皮肤表现,并抑制 PBMC 对 S. sanguinis 的细胞内 IFN-γ 反应,提示这种治疗具有免疫调节作用。

相似文献

1
Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease.阿奇霉素对贝赫切特病细胞内细胞因子反应和黏膜皮肤表现的影响。
Int J Dermatol. 2013 Dec;52(12):1561-6. doi: 10.1111/ijd.12144. Epub 2013 Jul 24.
2
Clinical and immunological effects of azithromycin in Behçet's disease.阿奇霉素对白塞病的临床及免疫学效应
J Oral Pathol Med. 2005 Jan;34(1):13-6. doi: 10.1111/j.1600-0714.2004.00265.x.
3
TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease.土耳其白塞病患者中肿瘤坏死因子-α基因1031位T/C多态性
Br J Dermatol. 2006 Aug;155(2):350-6. doi: 10.1111/j.1365-2133.2006.07348.x.
4
Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.依那西普治疗白塞病的短期试验:一项双盲、安慰剂对照研究。
J Rheumatol. 2005 Jan;32(1):98-105.
5
Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis.贝赫切特病葡萄膜炎患者对光感受器间维生素 A 结合蛋白和 S 抗原的免疫反应。
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3067-75. doi: 10.1167/iovs.09-4313. Epub 2010 Jan 20.
6
Behçet's disease: treatment of mucocutaneous lesions.白塞病:黏膜皮肤病变的治疗
Clin Exp Rheumatol. 2005 Jul-Aug;23(4):532-9.
7
Interferon-alpha treatment of Behçet's disease.α干扰素治疗白塞病。
J Rheumatol. 1998 Oct;25(10):1938-44.
8
Behçet's disease patients present high levels of deglycosylated anti-lipoteichoic acid IgG and high IL-8 production after lipoteichoic acid stimulation.白塞病患者在脂磷壁酸刺激后呈现出高水平的去糖基化抗脂磷壁酸IgG和高白细胞介素-8产生。
Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S27-34.
9
[Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].[白塞病——英夫利昔单抗治疗皮肤黏膜表现]
Acta Reumatol Port. 2009 Oct-Dec;34(4):633-40.
10
Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease.活动性白塞病患者中产生白细胞介素-2和干扰素-γ的T细胞频率增加。
Invest Ophthalmol Vis Sci. 1998 May;39(6):996-1004.

引用本文的文献

1
Innate immune responses in Behçet disease and relapsing polychondritis.白塞病和复发性多软骨炎中的固有免疫反应。
Front Med (Lausanne). 2023 Jun 26;10:1055753. doi: 10.3389/fmed.2023.1055753. eCollection 2023.
2
Treatment Options in Pediatric Behçet's Disease.儿童贝赫切特病的治疗选择。
Paediatr Drugs. 2023 Mar;25(2):165-191. doi: 10.1007/s40272-022-00548-5. Epub 2023 Jan 10.
3
Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.贝切特病口腔溃疡期间的唾液和血清细胞因子谱。
Front Immunol. 2021 Dec 22;12:724900. doi: 10.3389/fimmu.2021.724900. eCollection 2021.
4
Oral Health and Its Aetiological Role in Behçet's Disease.口腔健康及其在白塞病中的病因学作用。
Front Med (Lausanne). 2021 May 20;8:613419. doi: 10.3389/fmed.2021.613419. eCollection 2021.
5
Advances in the Treatment of Behcet's Disease.贝赫切特病治疗进展。
Curr Rheumatol Rep. 2021 May 20;23(6):47. doi: 10.1007/s11926-021-01011-z.
6
Triggering agents and microbiome as environmental factors on Behçet's syndrome.触发因素和微生物组作为环境因素对贝赫切特综合征的影响。
Intern Emerg Med. 2019 Aug;14(5):653-660. doi: 10.1007/s11739-018-2000-1. Epub 2018 Dec 6.
7
The assessment of contributing factors to oral ulcer presence in Behçet's disease: Dietary and non-dietary factors.白塞病口腔溃疡相关因素评估:饮食及非饮食因素
Eur J Rheumatol. 2018 Dec;5(4):240-243. doi: 10.5152/eurjrheum.2018.18094. Epub 2018 Oct 12.
8
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.白塞病的皮肤黏膜受累:过去几十年全身治疗的变化及未来展望
Mediators Inflamm. 2015;2015:451675. doi: 10.1155/2015/451675. Epub 2015 Jun 22.
9
Innate and Adaptive Responses to Heat Shock Proteins in Behcet's Disease.白塞病中对热休克蛋白的先天性和适应性反应。
Genet Res Int. 2013;2013:249157. doi: 10.1155/2013/249157. Epub 2013 Dec 31.